Avidin Ltd.

One of the most dinamic branch of Avidin Ltd. is to identify and develop novel anticancer compounds. In the frame of a Jedlik Ányos grant (AVINOMID, 2007) within a few month the company synthesized more than a hundred thalidomide analogues, from which we found very potent in vivo. These compounds are protected by a patent (owned by Avidin). This patent application will enter to PCT phase in 2008. In early 2008 the company made an agreement with the National Institute of Allergy and Infectious Diseases (“NIAID” 6700B Rockledge Drive, Bethesda, Maryland 20892, USA) to develop and test novel anti-Mycobacterium compounds. At present this project is financed only by Avidin’s own budget. At present the major focus of the company is to provide its services and products in the segment of functional genomics, pharmaceutical research and in the preclinical phase of analysing different drug candidates in Hungary and Europe.